What Is ABT Fair Value?
Abbott Laboratories (ABT) fair value estimate using multiple valuation models, updated daily.
As of August 1, 2026, Abbott Laboratories (ABT) has a composite fair value estimate of $85.11 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $105.70, suggesting the stock is overvalued by 19.5%.
Data as of August 1, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$85.11
vs. current price of $105.70(-19.5%)
How Is ABT Fair Value Calculated?
Four independent models estimate what ABT is worth. Each uses different inputs and assumptions. The composite blends them by weight.
ABT Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$109.53
+3.6%Fair Value
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$73.26
-30.7%Overvalued
Inputs used
ABT Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$60.91
-42.4%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$55.17
-47.8%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $105.70 is 3.6% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $7.82B | $7.29B |
| Year 2 | $8.49B | $7.38B |
| Year 3 | $9.21B | $7.46B |
| Year 4 | $9.99B | $7.55B |
| Year 5 | $10.84B | $7.64B |
| Year 6 | $11.76B | $7.73B |
| Year 7 | $12.77B | $7.82B |
| Year 8 | $13.85B | $7.91B |
| Year 9 | $15.03B | $8.00B |
| Year 10 | $16.31B | $8.10B |
| Terminal Value | $351.77B | $174.67B |
What Are ABT's Key Financial Metrics?
Earnings & Growth
Current Price
$105.70
EPS (TTM)
$3.09
Forward P/E
17.4
Profit Margin
11.6%
Cash & Balance Sheet
Free Cash Flow
7.2B
EBITDA
11.7B
Book Value
$29.89
Total Debt
32.7B
What Do Analysts Say About ABT?
Low
$103.00
Average
$118.42
High
$135.00
Upside
+12.0%
ABT Fair Value FAQ
What is the fair value of ABT?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), ABT's estimated fair value is $85.11. The stock is currently trading at $105.70, which makes it overvalued by our analysis.
How is ABT's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is ABT overvalued or undervalued?
Based on our analysis, ABT is overvalued. The current price of $105.70 is 19.5% above our estimated fair value of $85.11.
What do Wall Street analysts say about ABT?
24 analysts cover Abbott Laboratories with a consensus rating of "Buy." The average price target is $118.42, ranging from $103.00 to $135.00. This implies 12.0% upside from the current price.